Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Hubert PehambergerK Wolff

Abstract

Patients with primary cutaneous melanoma with a Breslow thickness > or = 1.5 mm have only a 30% to 70% probability of survival after surgery, and no adjuvant therapy has so far improved this outcome. Since interferon alfa-2a (IFNalpha2a) exhibits antitumor activity in metastatic melanoma, we investigated whether adjuvant IFNalpha2a diminishes the occurrence of metastases and thus prolongs disease-free survival in melanoma patients after excision of the primary tumor. In a prospective randomized study, 311 melanoma patients with a Breslow thickness > or = 1.5 mm were assigned to either adjuvant IFNalpha2a treatment (n = 154) or observation (n = 157) after excision of the primary tumor. IFNalpha2a was given daily at a dose of 3 mIU subcutaneously (s.c.) for 3 weeks (induction phase), after which a dose of 3 mIU s.c. three times per week was given over 1 year (maintenance phase). Prolonged disease-free survival was observed in patients treated with IFNalpha2a versus those who underwent surgery alone. This difference was significant (P = .02) for all patients enrolled onto the study (intention-to-treat analysis) at a mean observation time of 41 months. Subgroup analysis showed that Breslow tumor thickness had no influence on treatm...Continue Reading

Citations

Mar 22, 2002·Cancer Control : Journal of the Moffitt Cancer Center·Richard J GrayJohn M Kirkwood
Jul 26, 2002·Melanoma Research·P A AsciertoUNKNOWN Melanoma Cooperative Group of Naples
Jan 22, 2003·Internal Medicine Journal·P Hersey
Jul 2, 2005·Cancer Biotherapy & Radiopharmaceuticals·Michael FluckJens Atzpodien
Nov 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John M Kirkwood
May 15, 2007·Melanoma Research·Claus Garbe, Thomas K Eigentler
Feb 25, 2010·Journal of the National Cancer Institute·Simone MocellinDonato Nitti
Jun 1, 2010·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·K C KählerA Hauschild
Nov 5, 2010·Clinical and Vaccine Immunology : CVI·Luigi BuonaguroFranco M Buonaguro
Dec 20, 2012·Expert Review of Anticancer Therapy·Sanjiv S Agarwala
Jun 1, 2013·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Annette PflugfelderUNKNOWN German Society of Dermatology
Nov 13, 2014·PloS One·Martin ProbstKatharina Grabmeier-Pfistershammer
Apr 19, 2017·Current Oncology Reports·Aya Agha, Ahmad A Tarhini
May 31, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·M SchillerR Stadler
Dec 20, 2017·Current Opinion in Oncology·Florentia DimitriouJoanna Mangana
Feb 7, 2019·Cancer Immunology, Immunotherapy : CII·Lorena P Suarez-KellyWilliam E Carson
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Axel HauschildReinhard Dummer
Apr 12, 2003·American Journal of Clinical Dermatology·Sanjiv Agarwala
Apr 12, 2000·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·C C Otley, J A Zitelli
Jun 12, 2002·Current Treatment Options in Oncology·V K SondakL M Schuchter
Nov 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Erika RichtigUNKNOWN European Cooperative Adjuvant Melanoma Treatment Study Group
Aug 8, 2007·International Journal of Cancer. Journal International Du Cancer·Imke SatzgerRalf Gutzmer
Sep 17, 2005·HNO·E S Schultz, G Schuler
Apr 7, 2009·Experimental Dermatology·Carlo PincelliRiccardo G Borroni
Jul 11, 2007·The Cancer Journal·Gaurav D Shah, Paul B Chapman
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Axel HauschildClaus Garbe
Mar 29, 2012·The Cancer Journal·Diwakar DavarJohn M Kirkwood
Nov 5, 2011·Expert Review of Anticancer Therapy·John H Stewart, Edward A Levine
Oct 26, 2012·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·L ZimmerD Schadendorf
Feb 18, 2011·Medical Oncology·Gamze Gokoz DoguFerda Bir
Jul 30, 2015·HNO·C PföhlerC S L Müller
Nov 2, 2013·American Journal of Therapeutics·Helen GogasEnrique Espinosa
Oct 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter MohrMichael Weichenthal
Sep 20, 2017·Journal of the National Cancer Institute·Stefan SuciuMarc Buyse

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
E R KoomenH J Guchelaar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
S PyrhönenP L Kellokumpu-Lehtinen
© 2022 Meta ULC. All rights reserved